Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

A key part of Amgen’s strategy was to broaden the indications for those drugs it already owned, with Epogen successfully obtaining indications for anaemia in cancer patients, Enbrel broadening ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

In my opinion, thanks in part to Blincyto, Enbrel, Imdelltra, Tezspire, and Amjevita/Amgevita, Amgen is getting closer to the leaders in these markets, namely AstraZeneca (AZN) and Johnson ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The company projected 2025 revenue guidance, in range with average analyst consensus, with its top-selling drugs, Prolia and Enbrel, maintaining strong performance. "Amgen is a biotechnology ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer ...

Enbrel sales beat the Zacks Consensus Estimate of $864.0 million as well as our estimate of $874.5 million. Going forward, Amgen expects volumes to be flat for Enbrel, while net selling price is ...